NSCLC

Non-small-cell lung carcinoma is any type of epithelial lung cancer other than small-cell lung carcinoma. NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

Read more in the app

Long-term benefit of SABR for operable early-stage NSCLC shown in new study

Oncotarget: mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC

Patient-reported outcomes from the randomized phase III CROWN study of first-line Lorlatinib versus in ALK+ NSCLC

Adding ipilimumab to pembrolizumab does not improve efficacy in patients with NSCLC

Radiation Oncology trials using PET with FDG uptake among NSCLC patients

Sotorasib provides durable clinical benefit for patients with NSCLC and KRAS mutations